SCHOLAR ROCK HLDG DL-001
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to deve… Read more
SCHOLAR ROCK HLDG DL-001 (2QK) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, SCHOLAR ROCK HLDG DL-001 (2QK) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SCHOLAR ROCK HLDG DL-001 - Net Assets Trend (None–None)
This chart illustrates how SCHOLAR ROCK HLDG DL-001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SCHOLAR ROCK HLDG DL-001 (None–None)
The table below shows the annual net assets of SCHOLAR ROCK HLDG DL-001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to SCHOLAR ROCK HLDG DL-001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
SCHOLAR ROCK HLDG DL-001 Competitors by Market Cap
The table below lists competitors of SCHOLAR ROCK HLDG DL-001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
CSSC Offshore & Marine Engineering Group Co Ltd
SHG:600685
|
$2.75 Billion |
|
Klaviyo, Inc.
NYSE:KVYO
|
$2.75 Billion |
|
Greif Inc
NYSE:GEF-B
|
$2.75 Billion |
|
Hindustan Zinc Limited
NSE:HINDZINC
|
$2.75 Billion |
|
Delhivery Limited
NSE:DELHIVERY
|
$2.75 Billion |
|
Qingdao TGOOD Electric Co Ltd
SHE:300001
|
$2.75 Billion |
|
Zhonghang Electronic Measuring Instruments Co Ltd
SHE:300114
|
$2.74 Billion |
|
Bucher Industries AG
OTCGREY:BCHHF
|
$2.74 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SCHOLAR ROCK HLDG DL-001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares SCHOLAR ROCK HLDG DL-001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently SCHOLAR ROCK HLDG DL-001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares SCHOLAR ROCK HLDG DL-001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SCHOLAR ROCK HLDG DL-001 (2QK) | €- | N/A | N/A | $2.75 Billion |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |